Bristol Myers: Orencia Improves Survival in Hospitalized Covid-19 Patients

By Colin Kellaher

Bristol Myers Squibb Co. on Thursday said its blockbuster arthritis drug Orencia helped improve survival in a Phase 3 study in people hospitalized with Covid-19.

The New York biopharmaceutical company said treatment with Orencia versus placebo showed a strong but not statistically significant improvement in the primary endpoint of time to recovery as measured by day of hospital discharge in the study sponsored by the National Institutes of Health.

The study evaluated the safety and efficacy of a single dose of immune modulators, including Orencia, when given with standard of care to determine if modulating the immune system's response could speed recovery and reduce death in adults hospitalized with moderate to severe Covid-19.

Bristol Myers said analyses of the study's secondary endpoints, which included mortality and clinical status, showed Orencia reduced participants' risk of death and improved their clinical status at 28 days after entering the study when compared with placebo.

The company said Orencia's safety profile remained consistent, with no new safety signals reported in the study.

Bristol Myers said that given the positive study findings, it plans to discuss the data and potential next steps with the U.S. Food and Drug Administration.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

June 02, 2022 11:35 ET (15:35 GMT)

Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024